Lynn Seely was appointed Director of AbCellera Biologics Inc. As of November 6, 2026, AbCellera Biologics Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from June 5, 2026 to July 6, 2026, naming 2 appointments (Form 8-K, July 6, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like AbCellera Biologics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
AbCellera Biologics Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-06-05 to 2026-07-06. They name 2 people. Every row below is cited to the filing it comes from, and this page adds each new change as AbCellera Biologics Inc. files it.
Also on the record for AbCellera Biologics Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| May 7, 2026 | Stake report, Schedule 13G/A, by Baker Bros. Advisors LP | 10.8% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs AbCellera Biologics Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on AbCellera Biologics Inc. and the records around it.
AbCellera Biologics Inc. elsewhere on the record
- 5%+ stake filings May 2026
Companies that share a holder
- Baker Bros. Advisors LP also filed stake reports on 25 other companies: Madrigal Pharmaceuticals, Inc. (Nov 2026), Kodiak Sciences Inc. (Sep 2026), BeOne Medicines Ltd. (Sep 2026)
Watch AbCellera Biologics Inc.
Get an email when AbCellera Biologics Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on AbCellera Biologics Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on AbCellera Biologics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on AbCellera Biologics Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
3 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-07-06 | In | Director | 8-K, 2026-07-06 | ||
| 2026-06-05 | In | Director | 8-K, 2026-06-05 |
Who leads AbCellera Biologics Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Lynn Seely, appointed (filed 2026-07-06).
New leaders reset buying decisions — get the Full Report on AbCellera Biologics Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at AbCellera Biologics Inc., with the record behind each one.
Find candidates like Director at AbCellera Biologics Inc.Every change, in the filing's words
Appointed: Lynn Seely, Director
On June 30, 2026, the Board of Directors (the "Board") of AbCellera Biologics Inc. (the "Company") appointed Lynn Seely, M.D as a new Class III director.
- Dr. Seely will serve until the Company's 2029 annual meeting of shareholders and until her successor is duly elected and qualified, or until her earlier resignation or removal..
- The Board has affirmatively determined that Dr. Seely is independent under the rules of The NASDAQ Stock Market LLC and the Company's Corporate Governance Guidelines.
- Dr. Seely has not been appointed to serve on committees of the Board.
- In connection with Dr. Seely's service as a director, she will participate in the Company's Non-Employee Director Compensation Policy on the same terms as the Company's other non-employee directors, as previously disclosed in the Company's Definitive Proxy on Schedule 14A filed with the Securities and Exchange Commission on April 29, 2026.
Appointed: Victor Sandor, Director
On June 1, 2026, the Board of Directors (the "Board") of AbCellera Biologics Inc. (the "Company") appointed Victor Sandor as a new director.
- Dr. Sandor will serve until the Company's next annual meeting of shareholders and until his successor is duly elected and qualified, or until his earlier resignation or removal.
- The Board has affirmatively determined that Dr. Sandor is independent under the rules of The NASDAQ Stock Market LLC and the Company's Corporate Governance Guidelines.
- Dr. Sandor has not been appointed to serve on committees of the Board.
- In connection with Dr. Sandor's service as a director, he will participate in the Company's Non-Employee Director Compensation Policy on the same terms as the Company's other non-employee directors, as previously disclosed in the Company's Definitive Proxy on Schedule 14A filed with the Securities and Exchange Commission on April 29, 2026.
Tools for this story
Each opens in a new tab, filled in for AbCellera Biologics Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.